Published Nov 19, 2026 | 12:35 PM ⚊ Updated Nov 19, 2026 | 12:35 PM
Metformin works by reducing glucose production in the liver and improving the body's sensitivity to insulin.
Synopsis: Metformin, the main first-line medication for the treatment of type 2 diabetes, is being touted as a potential longevity drug, but clinical trials suggest it may blunt muscle growth and some metabolic benefits of exercise in older adults. Experts say its lifespan-extending benefits remain unproven and caution healthy, physically active people against taking it without a medical indication.
Metformin, the main first-line medication for the treatment of type 2 diabetes, is increasingly attracting attention for its potential to slow ageing and improve longevity. However, clinical trials have raised questions about whether the drug could interfere with some of the benefits of exercise, particularly muscle growth and improvements in mitochondrial function.
Two experts who spoke to South First said there is no conclusive clinical evidence that metformin slows biological ageing or extends lifespan in otherwise healthy people. They also cautioned against taking the medicine purely for longevity, particularly as research suggests it may blunt some of the adaptations that occur when people exercise.
“At present, there is no conclusive clinical evidence that taking metformin helps a healthy person without diabetes live longer or slow down ageing,” said Dr Prasanna Karthik S, senior consultant in diabetology and internal medicine at Gleneagles Hospital, Chennai, told South First.
Dr Naveen Kumar DS, diabetologist and general medicine specialist at Narayana Multispeciality Hospital, Mysore, said that although animal studies and observational research had generated interest in the drug’s potential to delay age-related diseases, these findings did not establish that it extends human lifespan.
“Changes in metabolic markers should not be mistaken for proven longevity benefits,” he said to South First.
Also Read: Your silver foil on sweets, paan may be aluminium: Hyderabad police bust four units
Metformin works by reducing glucose production in the liver and improving the body’s sensitivity to insulin, allowing cells to use glucose more effectively.
Unlike some other diabetes medicines, metformin does not directly stimulate insulin secretion and therefore has a relatively low risk of hypoglycaemia when used alone.
In recent years, researchers have examined whether the medicine could influence biological processes associated with ageing, including inflammation, cellular energy regulation and metabolism.
One of the pathways attracting attention is AMP-activated protein kinase (AMPK), an enzyme that helps regulate the body’s energy balance and metabolic processes.
“Metformin influences cellular pathways associated with ageing, including AMPK, which regulates energy balance, inflammation and metabolic processes,” Dr Naveen Kumar said.
However, he cautioned that the findings from animal studies and observational research were not sufficient to establish a longevity benefit in humans.
Dr Prasanna Karthik said the interest in metformin came from research suggesting that it could influence inflammation and the way cells use energy.
“But we need to separate research findings from proven benefits,” he said.
The question has gained attention following clinical trials examining how metformin interacts with exercise, particularly resistance training and aerobic activity.
Exercise stimulates several changes in the body, including improved insulin sensitivity, increased glucose uptake by muscles, better mitochondrial function and muscle growth.
Mitochondria are structures inside cells that produce most of the energy required for cellular activities. They generate adenosine triphosphate (ATP), which provides energy for processes such as muscle contraction.
Metformin can affect mitochondrial energy metabolism, including the activity of Complex I of the mitochondrial electron transport chain. This is one of the mechanisms being investigated to understand how the medicine influences glucose regulation.
A 2019 clinical trial published in Aging Cell, known as the MASTERS trial, examined whether metformin affected muscle growth in older adults undertaking resistance training.
The study included 94 participants aged 65 and above who completed 14 weeks of supervised resistance training. One group received metformin, while the other received a placebo.
Researchers found that participants receiving the placebo gained approximately 3.9 per cent thigh muscle mass, compared with 0.45 per cent among those taking metformin.
The placebo group also gained more lean body mass than the metformin group.
The findings suggested that metformin could blunt some of the muscle-building adaptations associated with resistance training in older adults.
Also Read: Children with Type 1 diabetes need more than insulin. Are schools equipped to support them?
Another clinical trial published in 2019 examined 53 older adults undertaking 12 weeks of aerobic exercise. Researchers found that metformin attenuated improvements in insulin sensitivity, cardiorespiratory fitness and skeletal muscle mitochondrial respiration.
Dr Naveen Kumar said these findings were clinically relevant, particularly for older adults.
“The MASTERS trial, published in Aging Cell in 2019, found that older adults taking metformin gained less lean body mass and thigh muscle mass following 14 weeks of resistance training compared with those receiving a placebo,” he said.
He added that another clinical trial had found that metformin attenuated improvements in mitochondrial respiration following aerobic exercise.
“These findings suggest that metformin may interfere with certain exercise adaptations. However, they do not establish that the medication universally prevents muscle growth,” he said.
Dr Prasanna Karthik also said that the findings needed attention, particularly among older adults.
“One clinical trial found that people taking metformin gained less muscle from resistance training compared with those who received a placebo. Other research has also suggested that it may reduce some of the improvements in mitochondrial function after aerobic exercise,” he said.
However, he cautioned against concluding that the medicine cancels out the benefits of exercise.
“I would not say that metformin cancels out the benefits of exercise, but it may interfere with some of the adaptations the body normally makes,” he said.
Also Read: Diabetes is a lifelong condition. Can Indian families afford a lifetime of treatment?
Age-related muscle loss, known as sarcopenia, can affect mobility, balance and physical independence. It can also increase the risk of frailty and falls among older adults.
The findings from the MASTERS trial have raised questions about whether metformin could affect the ability of older adults to build and preserve muscle through resistance training.
However, the trial examined muscle gains over 14 weeks. It did not establish that long-term metformin use causes sarcopenia.
Dr Naveen Kumar said sarcopenia was an important consideration because it increases the risk of frailty, falls and reduced independence.
“Older adults should prioritise resistance exercise, adequate protein intake and regular assessment of muscle strength,” he said.
Dr Prasanna Karthik said preserving muscle becomes increasingly important with age.
“Muscle loss can affect balance, mobility, independence and overall quality of life,” he said.
He added that maintaining muscle through strength training, adequate protein intake and regular physical activity should remain a priority.
Both doctors said more research was needed to understand the long-term implications of metformin’s effects on muscle preservation.
While metformin has an established role in managing type 2 diabetes, its potential use in healthy people without diabetes or prediabetes remains unproven.
Dr Naveen Kumar said there was currently insufficient clinical evidence to establish that the medicine provides additional longevity benefits to healthy, physically active individuals.
“Considering that metformin may attenuate certain exercise adaptations, taking it without a medical indication offers no established advantage,” he said.
Dr Prasanna Karthik also questioned the need to take the medicine among people who already exercise regularly and have normal blood glucose levels.
“For someone who is already healthy, exercises regularly and has normal blood sugar levels, I don’t see enough evidence to recommend adding metformin,” he said.
He added that exercise itself improves insulin sensitivity, cardiovascular health and overall metabolic function.
“If there is no medical indication for the medicine, we cannot assume that taking it will provide an additional benefit,” he said.
Also Read: US recommends regular prostate cancer screening for men aged 50-69
Like other medicines, metformin can cause side effects. These include nausea, diarrhoea and abdominal discomfort. Long-term use can also reduce vitamin B12 absorption, potentially leading to deficiency, anaemia and neurological complications.
A rare but serious complication is lactic acidosis, particularly among people with significant kidney impairment and certain other medical conditions.
Dr Naveen Kumar said he would not recommend metformin routinely to healthy individuals without diabetes or prediabetes purely for longevity.
He also pointed to the possibility of vitamin B12 deficiency with long-term use and the need for caution among people with kidney impairment.
Dr Prasanna Karthik similarly said that the medicine should be prescribed when there was a clear medical reason.
“A medicine should be prescribed when there is a clear medical reason, not simply because it is being discussed as an anti-ageing drug,” he said.
Both doctors emphasised that people prescribed metformin for diabetes should not discontinue it independently because of the findings on exercise and muscle growth.
For healthy people interested in ageing well, Dr Naveen Kumar said regular exercise, balanced nutrition, adequate sleep and management of metabolic risk factors should remain the focus.
(Edited by Dese Gowda)